<div id="readability-page-1"><p><span>Arcellx (NASDAQ:ACLX - Get Free Report)</span> was upgraded by research analysts at Truist Financial to a &#34;strong-buy&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p><p>Several other equities research analysts also recently weighed in on the stock. TD Cowen lowered shares of Arcellx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, March 2nd. Guggenheim lowered Arcellx from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their price objective for the company from $120.00 to $115.00 in a report on Wednesday, February 25th. Leerink Partners  reissued a &#34;market perform&#34; rating and issued a $115.00 price objective on shares of Arcellx in a research report on Tuesday, February 24th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Arcellx in a research note on Monday, April 20th. Finally, William Blair cut Arcellx from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, February 23rd. One equities research analyst  has rated the stock with a Strong Buy rating, one  has issued  a Buy rating, sixteen have given a Hold rating and one  has given a Sell rating to the company. According to MarketBeat.com, the stock  has an average rating of &#34;Hold&#34; and a consensus price target of $111.87.</p><p><b>Read Our Latest Report on Arcellx</b></p><h2>Arcellx Price Performance</h2><p>Shares of ACLX stock opened at $115.10 on Monday. Arcellx has a 1-year low of $47.86 and a 1-year high of $115.13. The stock's 50-day moving average is $110.81 and its 200 day moving average is $87.46. The company has a market cap of $6.73 billion, a P/E ratio of -28.28 and a beta of 0.25. </p><p>Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($1.01). Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. The business had revenue of $1.65 million for the quarter, compared to analysts' expectations of $13.40 million.  On average, analysts anticipate that  Arcellx will post -2.91 EPS for the current year. </p><h2>Insiders Place Their Bets</h2><p>In other news, insider Rami Elghandour sold 89,916 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the transaction, the insider directly owned 276,051 shares of the company's stock, valued at approximately $31,447,729.92. This represents a 24.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders own  8.35% of the company's stock. </p><h2>Hedge Funds Weigh In On Arcellx</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in  Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock worth $1,893,000 after buying an additional 1,390 shares during the last quarter.  Empowered Funds LLC purchased a new stake in shares of  Arcellx in the 1st quarter valued at $1,768,000.  Intech Investment Management LLC boosted its holdings in shares of  Arcellx by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock valued at $1,441,000 after acquiring an additional 4,760 shares during the last quarter.  Prudential Financial Inc. raised its holdings in shares of  Arcellx by 49.2% during the second quarter. Prudential Financial Inc. now owns 4,900 shares of the company's stock worth $323,000 after purchasing an additional 1,615 shares during the last quarter.  Finally, Norges Bank purchased a new position in shares of  Arcellx during the second quarter worth $739,000. Institutional investors and hedge funds own  96.03% of the company's stock. </p><h2>About Arcellx</h2> (Get Free Report)<p>Arcellx, Inc <span>NASDAQ: ACLX<span></span></span> is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.  </p><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p><h2>See Also</h2><ul><li>Five stocks we like better than Arcellx</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arcellx Right Now?</h2><p>Before you consider Arcellx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p><p>While Arcellx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACLX

<p>Truist Financial upgraded Arcellx (NASDAQ:ACLX) to a "strong-buy" rating. Other analysts have mixed views, with TD Cowen downgrading it to "hold" and Guggenheim lowering its price target. The stock opened at $115.10, with a 1-year range of $47.86 to $115.13. Arcellx reported a quarterly loss of ($1.01) EPS, missing revenue expectations. Insiders sold shares, and institutional investors hold 96.03% of the stock. Arcellx focuses on developing cell therapies for oncology and autoimmune diseases.</p>

Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial